Przejdź do zawartości
Merck

Cisplatin induces production of reactive oxygen species via NADPH oxidase activation in human prostate cancer cells.

Free radical research (2011-06-21)
Tomohiro Itoh, Riyako Terazawa, Keitaro Kojima, Keita Nakane, Takashi Deguchi, Masashi Ando, Yasuyuki Tsukamasa, Masafumi Ito, Yoshinori Nozawa
ABSTRAKT

This study aimed to examine the roles of reactive oxygen species (ROS) in cisplatin treatment of human prostate cancer cells; hormone-sensitive LNCaP and hormone-refractory PC3 and DU145 cells. Intracellular levels of ROS and H(2)O(2) were measured and visualized using specific fluorescent probes. NADPH oxidase (NOX) activity was detected by lucigenin chemiluminescence assay. Expression levels of NOX isoforms were determined by semi-quantitative RT-PCR. Cisplatin treatment increased the intracellular levels of ROS and H(2)O(2) in three prostate cancer cell lines. The increase was transient and robust in hormone-sensitive LNCaP cells compared with hormone-refractory PC3 and DU145 cells. Consistent with these findings, the NOX activity induced by cisplatin was higher in LNCaP cells than in PC3 and DU145 cells. Expression pattern of NOX isoforms varied among three cell lines and the NOX activity was independent of NOX expression. Taken together, we have shown that cisplatin induces production of ROS and H(2)O(2) via NOX activation in human prostate cancer cell lines, which is most prominent in hormone-sensitive LNCaP cells.

MATERIAŁY
Numer produktu
Marka
Opis produktu

Sigma-Aldrich
BES, ≥99.0% (titration)